# Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma

> **NCT01453504** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Cologne** · enrollment: 73 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** DHAP
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01453504
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01453504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01453504, "Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT01453504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*